Quote:Nexavar costs an estimated $69,000 for a full year of treatment in India, 41 times the country’s annual per capita income.
In 2012, Indian pharmaceutical company Natco Pharma Ltd. applied for just such a license, and it was granted. The company began reproducing the drug at a 97 percent discount, offering it for just $177.
Note that the 97% discount results in a $177 montly cost (which is still above the per capita income). I hate it when journalists mix units like this - it's not as if an apples to apples comparison isn't bad enough.